Novell Pharma




Genemax Healthcare
Concise Prescribing Info
Ketorolac tromethamine
Short-term treatment/therapy of moderate to severe acute post-op pain.
Dosage/Direction for Use
Adult IM 60 mg as single dose to be given slowly & deeply into the muscle. IV 30 mg as single dose IV bolus over no <15 sec. Multiple dose: IV/IM 30 mg 6 hrly. Max: 120 mg once daily. Childn IM Max: 30 mg as single dose. IV Max: 15 mg as single dose. Elderly ≥65 yr, renally impaired &/or weighing <50 kg IM 30 mg slowly & deeply into the muscle, IV 15 mg IV bolus over no <15 sec, IV/IM 15 mg 6 hrly. Max: 60 mg once daily.
Hypersensitivity to ketorolac or other NSAIDs. Nasal polyp, angioedema or bronchospasm. Moderate or severe renal impairment or at risk of renal failure due to vol depletion. Severe heart failure. Suspected or confirmed cerebrovascular bleeding, hemorrhagic diathesis, incomplete hemostasis or high risk of bleeding. Prophylactic analgesic before surgery or intra-operatively. Treatment of perioperative pain in CABG surgery. Neuraxial (epidural or intrathecal) administration. Concomitant use w/ probenecid, lithium salts, aspirin, other NSAIDs or anticoagulants (eg, warfarin, heparin). Pregnancy, labour, delivery or lactation.
Special Precautions
Not recommended for use as a pre-op medication for the support of anesth & as an obstetrical pre-op medication or for obstetrical analgesic. Contraindicated in patients w/ history of asthma, urticaria or acute rhinitis caused by aspirin or NSAIDs, GI bleeding or perforation, severe hepatic failure & renal failure, & dengue fever. Increased risk of bleeding or ulceration on GI tract; increased risk of brain vascular & CV narrowing especially for prolonged use w/ high dosage. Patients w/ cardiac & renal dysfunction; HTN. Avoid in patients w/ suspected dengue fever or other platelet disorders; pregnancy (last quarter). Lactation. Childn <2 yr. Elderly.
Adverse Reactions
Edema, HTN. Dyspepsia, nausea, GI pain, diarrhea, constipation, flatulence, vomiting, stomatitis, peptic ulcer, GI bleeding. Headache, somnolence or drowsiness, dizziness. IM: pain at inj site, ecchymosis, bruising, hematoma, pruritus, sweating & tingling at the inj site. Blurred vision. Borderline elevations of ≥1 liver function tests results. Elevations of serum urea, creatinine & K.
Drug Interactions
May increase risk of bleeding w/ anticoagulants (eg, warfarin, heparin). May increase risk of renal impairment w/ ACE inhibitors. May increase risk of developing renal failure w/ & reduced natriuretic effects of diuretics. Seizures may occur w/ anticonvulsants eg, phenytoin, carbamazepine. Hallucinations may occur w/ psychoactive drugs eg, fluoxetine, thothixene, alprazolam. Reduced clearance & enhanced toxicity of methotrexate. Decreased clearance & increased plasma level w/ probenecid. Increased plasma conc of lithium.
ATC Classification
M01AB15 - ketorolac ; Belongs to the class of acetic acid derivatives and related substances of non-steroidal antiinflammatory and antirheumatic products.
Xevolac inj 30 mg/mL
6 × 1's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in